keyword
MENU ▼
Read by QxMD icon Read
search

Low-dose naltrexone

keyword
https://www.readbyqxmd.com/read/29438157/effects-of-varenicline-alone-and-in-combination-with-low-dose-naltrexone-on-alcohol-primed-smoking-in-heavy-drinking-tobacco-users-a-preliminary-laboratory-study
#1
Walter Roberts, Julia M Shi, Jeanette M Tetrault, Sherry A McKee
OBJECTIVES: Heavy-drinking tobacco users are less likely to successfully quit smoking than their moderate-drinking counterparts, even when they are prescribed smoking cessation medication. One strategy for improving treatment outcomes in this subgroup of tobacco users may be to combine medication therapies to target both alcohol and tobacco use simultaneously. Adding naltrexone to frontline smoking cessation treatments may improve treatment outcomes in this group. METHOD: This double-blind, placebo-controlled human laboratory study examined the effects of varenicline (2 mg/d) and varenicline (2 mg/d), combined with a low dose of naltrexone (25 mg/d) on alcohol-primed smoking behavior in a laboratory model of smoking relapse in heavy-drinking tobacco users (n = 30)...
February 12, 2018: Journal of Addiction Medicine
https://www.readbyqxmd.com/read/29385430/the-effect-of-low-dose-naltrexone-on-medication-in-inflammatory-bowel-disease-a-quasi-experimental-before-and-after-prescription-database-study
#2
Guttorm Raknes, Pia Simonsen, Lars Småbrekke
Background and Aims: Low dose naltrexone (LDN) is a controversial off-label treatment used by many Crohn's disease (CD) and ulcerative colitis (UC) patients. A small number of preliminary studies indicate that LDN might be beneficial in CD, but evidence is too scarce to demonstrate efficacy. We wanted to examine whether initiation of LDN therapy by patients with inflammatory bowel disease (IBD) was followed by changes in dispensing of relevant medication. Methods: We performed a quasi-experimental before and after study following a sudden increase of LDN use in the Norwegian population in 2013...
January 27, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29377216/the-safety-and-efficacy-of-low-dose-naltrexone-in-the-management-of-chronic-pain-and-inflammation-in-multiple-sclerosis-fibromyalgia-crohn-s-disease-and-other-chronic-pain-disorders
#3
Denise K Patten, Bob G Schultz, Daniel J Berlau
Chronic inflammatory diseases are complex to treat and have an impact on a large number of patients. Due to the difficulty of treating these diseases and the great impact on quality of life, patients often seek off-label, complimentary, or alternative medicines to gain relief from symptoms. Low-dose naltrexone has been used off-label for treatment of pain and inflammation in multiple sclerosis, Crohn's disease, fibromyalgia, and other diseases. Naltrexone is a mu-opioid receptor antagonist indicated by the Food and Drug Administration for opioid and alcohol dependence...
January 27, 2018: Pharmacotherapy
https://www.readbyqxmd.com/read/29326369/successful-treatment-of-postural-orthostatic-tachycardia-and-mast-cell-activation-syndromes-using-naltrexone-immunoglobulin-and-antibiotic-treatment
#4
Leonard B Weinstock, Jill B Brook, Trisha L Myers, Brent Goodman
A patient with severe postural orthostatic tachycardia syndrome (POTS) and mast cell activation syndrome (MCAS) received immunotherapy with low-dose naltrexone (LDN) and intravenous immunoglobulin (IVIg) and antibiotic therapy for small intestinal bacterial overgrowth (SIBO). A dramatic and sustained response was documented. The utility of IVIg in autoimmune neuromuscular diseases has been published, but clinical experience with POTS is relatively unknown and has not been reported in MCAS. As a short-acting mu-opioid antagonist, LDN paradoxically increases endorphins which then bind to regulatory T cells which regulate T-lymphocyte and B-lymphocyte production and this reduces cytokine and antibody production...
January 11, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29273103/emerging-unconventional-therapies-for-alopecia-areata
#5
Natasha Atanaskova Mesinkovska
Alopecia areata is a prevalent autoimmune skin disease with no cure or indicated treatment options. In the absence of an approved treatment, some patients are eager to try unconventional therapies, despite the very limited research evaluating their safety and efficacy. Recently emerging unconventional therapies for alopecia areata discussed include antihistamines, cryotherapy, and low-dose naltrexone.
January 2018: Journal of Investigative Dermatology. Symposium Proceedings
https://www.readbyqxmd.com/read/29258346/the-long-term-survival-of-a-patient-with-stage-iv-renal-cell-carcinoma-following-an-integrative-treatment-approach-including-the-intravenous-%C3%AE-lipoic-acid-low-dose-naltrexone-protocol
#6
Burton M Berkson, Francisco Calvo Riera
In this case report, we describe the treatment of a 64-year-old male patient diagnosed with metastatic renal cell carcinoma (RCC) in June of 2008. In spite of a left nephrectomy and the standard oncological protocols, the patient developed a solitary left lung metastasis that continued to grow. He was informed that given his diagnosis and poor response to conventional therapy, any further treatment would, at best, be palliative. The patient arrived at the Integrative Medical Center of New Mexico in August of 2010...
December 1, 2017: Integrative Cancer Therapies
https://www.readbyqxmd.com/read/29222923/co-administration-of-low-dose-naltrexone-and-bupropion-reduces-alcohol-drinking-in-alcohol-preferring-p-rats
#7
Emily R Nicholson, Julian E Dilley, Janice C Froehlich
BACKGROUND: This study examined whether combining naltrexone (NTX) with bupropion (BUP) is more effective in reducing alcohol drinking in alcohol-preferring (P) rats with a genetic predisposition toward high voluntary alcohol intake than is either drug alone. METHODS: Alcohol-experienced, adult, male, alcohol-preferring (P) rats were fed NTX alone in a dose of 10.0 mg/kg BW, BUP alone in a dose of 10.0 mg/kg BW, BUP alone in a dose of 20.0 mg/kg BW, NTX (10.0 mg/kg BW) + BUP (10...
December 9, 2017: Alcoholism, Clinical and Experimental Research
https://www.readbyqxmd.com/read/29194445/safety-and-efficacy-of-an-oxycodone-vaccine-addressing-some-of-the-unique-considerations-posed-by-opioid-abuse
#8
M D Raleigh, S J Peterson, M Laudenbach, F Baruffaldi, F I Carroll, S D Comer, H A Navarro, T L Langston, S P Runyon, S Winston, M Pravetoni, P R Pentel
Among vaccines aimed at treating substance use disorders, those targeting opioids present several unique medication development challenges. 1) Opioid overdose is a common complication of abuse, so it is desirable for an opioid vaccine to block the toxic as well as the addictive effects of opioids. 2) It is important that an opioid vaccine not interfere with the action of opioid antagonists used to reverse opioid overdose or treat addiction. 3) Some opioids are immunosuppressive and chronic ongoing opioid use could interfere with vaccine immunogenicity...
2017: PloS One
https://www.readbyqxmd.com/read/29141063/novel-treatment-using-low-dose-naltrexone-for-lichen-planopilaris
#9
Lauren C Strazzulla, Lorena Avila, Kristen Lo Sicco, Jerry Shapiro
<p>Lichen planopilaris (LPP) is a variant of lichen planus that affects the scalp causing scarring hair loss. Patients also frequently experience symptoms of scalp itch, pain, and burning. To date, there are no long-term remittive nor curative therapies available. Low-dose naltrexone has anti-inflammatory properties and has recently been described in the context of treating autoimmune conditions. This retrospective medical record review describes four LPP patients treated with low-dose (3 milligrams per day) naltrexone...
November 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/29132230/combination-therapy-for-obesity
#10
John Ph Wilding
Obesity is a chronic disease with serious consequences and although lifestyle modification is considered first line treatment, it is often ineffective, especially in the long term. Relatively few people with obesity will undergo the most effective currently available treatment of bariatric surgery. Pharmacotherapy can bridge the gap between lifestyle modification and surgery, but many monotherapies have only modest efficacy or require high doses with unacceptable side effects. As with many other areas of medicine, combination therapy is now becoming accepted as a way of optimising efficacy for weight management, whilst minimising adverse effects...
November 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/29122501/psychoneuroimmunological-approach-to-gastrointestinal-related-pain
#11
REVIEW
Karlo Toljan, Bruce Vrooman
BACKGROUND AND PURPOSE (AIMS): Psychoneuroimmunology is both a theoretical and practical field of medicine in which human biology and psychology are considered an interconnected unity. Through such a framework it is possible to elucidate complex syndromes in gastrointestinal related pain, particularly chronic non-malignant. The aim is to provide insight into pathophysiological mechanisms and suggest treatment modalities according to a comprehensive paradigm. The article also presents novel findings that may guide clinicians to recognize new targets or scientists to find new research topics...
October 2017: Scandinavian Journal of Pain
https://www.readbyqxmd.com/read/29105118/v1b-receptor-antagonist-ssr149415-and-naltrexone-synergistically-decrease-excessive-alcohol-drinking-in-male-and-female-mice
#12
Yan Zhou, Marcelo Rubinstein, Malcolm Low, Mary Jeanne Kreek
BACKGROUND: A recent clinical trial found that pharmacological blockade of V1b receptors reduces alcohol relapse in alcohol-dependent patients. SSR149415 is a selective V1b receptor antagonist that has potential for development as an alcohol dependency treatment. In this study, we investigated whether SSR149415 alone or in combination with the mu-opioid receptor [MOP-r] antagonist naltrexone (NTN) would alter excessive alcohol drinking in mice. METHODS: Both sexes of C57BL/6J (B6) mice were subjected to a chronic intermittent access (IA) drinking paradigm (two-bottle choice, 24-h access every other day) for 3 weeks...
November 3, 2017: Alcoholism, Clinical and Experimental Research
https://www.readbyqxmd.com/read/29100152/corrigendum-to-randomized-proof-of-concept-trial-of-low-dose-naltrexone-for-patients-with-breakthrough-symptoms-of-major-depressive-disorder-on-antidepressants-j-affect-disord-208-2017-jan-15-6-14-doi-10-1016-j-jad-2016-08-029-epub-2016-oct-1
#13
D Mischoulon, L Hylek, A S Yeung, A J Clain, L Baer, C Cusin, D F Ionescu, J E Alpert, D P Soskin, M Fava
No abstract text is available yet for this article.
October 27, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29099849/low-dose-naltrexone-in-multiple-sclerosis-effects-on-medication-use-a-quasi-experimental-study
#14
Guttorm Raknes, Lars Småbrekke
Low dose naltrexone (LDN) has become a popular off-label therapy for multiple sclerosis (MS). A few small, randomized studies indicate that LDN may have beneficial effects in MS and other autoimmune diseases. If proven efficacious, it would be a cheap and safe alternative to the expensive treatments currently recommended for MS. We investigated whether a sudden increase in LDN use in Norway in 2013 was followed by changes in dispensing of other medications used to treat MS. We performed a quasi-experimental before-and-after study based on population data from the Norwegian Prescription Database (NorPD)...
2017: PloS One
https://www.readbyqxmd.com/read/28991360/low-dose-naltrexone-a-novel-treatment-for-hailey-hailey-disease
#15
V Campbell, C McGrath, A Corry
Hailey-Hailey disease (chronic benign familial pemphigus) is a rare inherited dermatosis typically characterised by erosions at intertriginous sites preceded by minor trauma or stress. We report a case of treatment resistant Hailey-Hailey disease, having failed topical and oral steroids, prophylactic acyclovir and doxycycline, and systemic therapies including dapsone, acitretin and ciclosporin. Low dose naltrexone (LDN) 4.5mg one daily was commenced following an incidental benefit in this patient's similarly affected sister...
October 9, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28947376/antagonising-tlr4-trif-signalling-before-or-after-a-low-dose-alcohol-binge-during-adolescence-prevents-alcohol-drinking-but-not-seeking-behaviour-in-adulthood
#16
Jonathan Henry Jacobsen, Femke Buisman-Pijlman, Sanam Mustafa, Kenner C Rice, Mark R Hutchinson
Adolescents frequently engage in risky behaviours such as binge drinking. Binge drinking, in turn, perturbs neurodevelopment reinforcing reward seeking behaviour in adulthood. Current animal models are limited in their portrayal of this behaviour and the assessment of neuroimmune involvement (specifically the role of Toll-like receptor 4 (TLR4)). Therefore, the aims of this project were to develop a more relevant animal model of adolescent alcohol exposure and to characterise its effects on TLR4 signalling and alcohol-related behaviours later life...
September 22, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28868795/ultra-low-doses-of-naltrexone-enhance-the-antiallodynic-effect-of-pregabalin-or-gabapentin-in-neuropathic-rats
#17
Jorge B Pineda-Farias, Nadia L Caram-Salas, Ana B Salinas-Abarca, Jorge Ocampo, Vinicio Granados-Soto
Preclinical Research Treatment of neuropathic pain is an area of largely unmet medical need. Pregabalin and gabapentin are anticonvulsants widely used for the treatment of neuropathic pain. Unfortunately, these drugs are only effective in 50-60% of the treated patients. In addition, both drugs have substantial side effects. Several studies have reported that ultralow doses of opioid receptor antagonists can induce analgesia and enhance the analgesic effect of opioids in rodents and humans. The objective of the present study was to assess the antiallodynic synergistic interaction between gabapentinoids and naltrexone in rats...
December 2017: Drug Development Research
https://www.readbyqxmd.com/read/28768314/low-dose-naltrexone-treatment-of-familial-benign-pemphigus-hailey-hailey-disease
#18
Omer Ibrahim, Sara R Hogan, Alok Vij, Anthony P Fernandez
Importance: Familial benign pemphigus, or Hailey-Hailey disease (HHD), is a rare and debilitating genetic dermatosis characterized by chronic, recurrent vesicles, erosions, and maceration in flexural areas. Despite the reported therapeutic modalities, such as topical and systemic corticosteroids, systemic immunomodulators, topical and systemic retinoids, and laser, HHD can still be markedly difficult to control. Objective: To assess low-dose naltrexone hydrochloride in the treatment of recalcitrant HHD...
October 1, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28768313/treatment-of-hailey-hailey-disease-with-low-dose-naltrexone
#19
Lauren N Albers, Jack L Arbiser, Ron J Feldman
Importance: Hailey-Hailey disease is a severe genetic blistering disease of intertriginous skin locations that can lead to poor quality of life and increased morbidities. Multiple therapies are available with inconsistent outcomes and potentially severe adverse effects. Objective: To determine whether low-dose naltrexone is an effective treatment for Hailey-Hailey disease. Design, Setting, and Participants: This study was a case series performed at a dermatology outpatient clinic of 3 patients with severe Hailey-Hailey disease recalcitrant to at least 4 therapies...
October 1, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28766982/featured-article-serum-met5-enkephalin-levels-are-reduced-in-multiple-sclerosis-and-restored-by-low-dose-naltrexone
#20
Michael D Ludwig, Ian S Zagon, Patricia J McLaughlin
Low-dose naltrexone is a widely used off-label therapeutic prescribed for a variety of immune-related disorders. The mechanism underlying low-dose naltrexone's efficacy for fatigue, Crohn's disease, fibromyalgia, and multiple sclerosis is, in part, intermittent blockade of opioid receptors followed by upregulation of endogenous opioids. Short, intermittent blockade by naltrexone specifically blocks the opioid growth factor receptor resulting in biofeedback events that increase production of the endogenous opioid growth factor (OGF) (chemically termed [Met5]-enkephalin) facilitating interactions between opioid growth factor and opioid growth factor receptor that ultimately, result in inhibited cell proliferation...
September 2017: Experimental Biology and Medicine
keyword
keyword
62670
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"